ClinicalTrials.gg
TerminatedNCT04945824Updated Feb 6, 2023

A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects

An Early Phase 1 interventional study of Dexamethasone Ophthalmic and Dilator in Healthy, sponsored by Ocular Therapeutix, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-06.

Sponsored by Ocular Therapeutix, Inc. · Early Phase 1, Interventional, and Other

Why this study was terminated
inserter device did not perform as expected

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multi-center, bilateral, human factors study designed to evaluate the utilization and safety of a novel intracanalicular insertion device in healthy subjects and to evaluate the concentration of DEXTENZA in tears. Each subject's participation is expected to last for approximately 1 month from the DEXTENZA insertion.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are a healthy adult subject aged 18 years or older with no known significant health problems
  • Are willing to refrain from wearing contact lens for the duration of the study
  • Are willing and able to comply with clinic visits and study related procedures
  • Are willing and able to sign the form

Exclusion criteria

Exclusion Criteria:

  • Have known significant health problems
  • Are women of
  • Are breastfeeding
  • Are a known responder
  • Have a history of herpes simplex virus keratitis or present active bacterial, viral, or fungal keratitis in either eye
  • Have a history of complete punctal occlusion in one or both punctum
  • Currently use topical ophthalmic steroid medications
  • Are unwilling or unable to comply with the study protocol
  • Are determined by the Investigator to not be included for reasons not already specified (e.g., systemic, behavioral, or other ocular
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Novel Intracanalicular Insertion Device

    Drug: Dexamethasone Ophthalmic · Device: Dilator

Interventions

  • Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.

  • DeviceDilator

    Intracanalicular Dilator Device

06

What researchers measure

Primary outcomes

  1. Ease of insertion as assessed by Post-Insertion Investigator Questionnaire

    Time frame: Assessed at Visit 1 (Day 1)

07

Study locations

1 site
  • Ocular Therapeutix, Inc.
    Sioux Falls, South Dakota 57108, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Nov 2022, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2021
First posted
Jun 30, 2021
StartActual
Jun 1, 2021
Primary completionActual
Nov 1, 2022
CompletionActual
Nov 1, 2022
Last update
Feb 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04945824
Responsible party
Sponsor
First posted
Jun 30, 2021
Start date
Jun 1, 2021
Primary completion
Nov 1, 2022
Completion
Nov 1, 2022
Last update
Feb 6, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion